Key result
Apolipoprotein E ε4 carriers were referred to a specialized lipid clinic at a significantly younger age (44.2 vs 50.6 years) and had a poorer total cholesterol reduction (-11.8% vs -19.9%) compared to non-carriers.
Why the study?
Is the apoE ε4 polymorphism associated with younger age at referral to a lipid clinic and poorer response to lipid-lowering therapy in patients with dyslipidemia?
Population
463 patients followed at a specialized lipid clinic due to dyslipidemia
Comparison
ApoE ε4 carrier status vs Non-ε4 carrier status
Design
Cohort, Primary care physician at the time of referral had no access to the…
Follow-up
3-year median
Authors
Loading...
ε4 carriers may need earlier referral and closer statin monitoring; leaves open whether genotyping improves dyslipidemia outcomes.
Observational (n=463)
No
Is the apoE ε4 polymorphism associated with younger age at referral to a lipid clinic and poorer response to lipid-lowering therapy in patients with dyslipidemia?
Absolute Event Rate: 44.2% vs 50.6%
p-value: p=<0.001
ApoE ε4 carriers with dyslipidemia are referred to specialized clinics at a younger age and exhibit a blunted cholesterol-lowering response to statin therapy compared to non-carriers.
Baptista et al. (2011) conducted an observational in Dyslipidemia (n=463). Apolipoprotein E epsilon-4 (apoE ε4) carrier status vs. Non-ε4 carriers was evaluated on Age at referral (p=<0.001). Apolipoprotein E ε4 carriers were referred to a specialized lipid clinic at a significantly younger age (44.2 vs 50.6 years) and had a poorer total cholesterol reduction (-11.8% vs -19.9%) compared to non-carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: